Mor Moskovitz

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

Elizabeth Dudnik, Nir Peled, Hovav Nechushtan et al. · Journal of Thoracic Oncology · 2018 · 219 citations · Full text

Tumor Mutational Burden, Death Ligand 1, Medicine +9

Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome

Gil Bar‐Sela, Idan Cohen, Salvatore Campisi‐Pinto et al. · Cancers · 2020 · 124 citations · Full text

Poor Clinical Outcome, Cancer Management, Immunology +22

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 123 citations · Full text

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park et al. · Nature Medicine · 2024 · 102 citations · Full text

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data

Elizabeth Dudnik, Mor Moskovitz, Sameh Daher et al. · Lung Cancer · 2017 · 101 citations

Real-life Data, Medicine, Cancer Management +7